Skip to main content

Advertisement

Fig. 5 | BMC Medicine

Fig. 5

From: Metabolomics approaches in pancreatic adenocarcinoma: tumor metabolism profiling predicts clinical outcome of patients

Fig. 5

Impact of neoadjuvant chemotherapy on pancreatic adenocarcinoma (PA). PA with neoadjuvant chemotherapy-related samples (n = 62) were compared to PA without neoadjuvant chemotherapy (n = 44). Metabolic network analysis according to ADEMA results. The red, green, and blue arrows, respectively, indicate the metabolites that are predicted to increase, decrease, or remain stable in PA with neoadjuvant chemotherapy-related samples

Back to article page